Vaxine
Company Details
Status: Private
Employees: 11-50
Location:
Bedford Park, Australia
Type:
sample
Technology:
sample
sample
About: Vaxine was incorporated in 2002 as an Australian biotechnology company focussing on development of innovative vaccine technologies, with its lead product being its Advax delta inulin adjuvant. Supported by funding contracts from the National Institutes of Health Vaxine has developed a broad range of vaccines, all utilizing its Advax adjuvant technology for enhanced immunogenicity and protection. Vaxine’s human candidates include vaccines against seasonal and pandemic influenza, COVID-19, hepatitis B, Japanese encephalitis, West Nile Virus, malaria, rabies, and allergy. Vaxine also has a veterinary division that is commercialising vaccine adjuvants tailored to specific animal health problems.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Vaxine | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.